Abstract B015: An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Jenny Y. Xue(Memorial Sloan Kettering Cancer Center), Piro Lito(Memorial Sloan Kettering Cancer Center), Luciano G. Martelotto(Centre for Cancer Biology), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), Scott W. Lowe(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Neal Rosen(Memorial Sloan Kettering Cancer Center), Jorge S. Reis‐Filho(AstraZeneca (France)), Alberto Vides(Memorial Sloan Kettering Cancer Center), Timour Baslan(University of Pennsylvania), Martha Solomon(Memorial Sloan Kettering Cancer Center), Elisa DeStanchina(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k